Emerging evidence indicates JAK inhibitors could be a valuable alternative for managing checkpoint inhibitor–induced immune ...

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

Patients with axSpA who received UPA reported rapid and sustained improvements in total and nocturnal back pain over 12 weeks.

“Given the heterogeneity found among patients with CD, the fact that [upadacitinib] is currently not approved for first-line use, and prior off-label usage of [tofacitinib] in many patients with ...

About Upadacitinib (RINVOQ®)Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory ...

Top-line results of part one of the study were shared in April 2024 . For more information regarding this study, please visit ClinicalTrials (identifier: NCT03725202). About Upadacitinib (RINVOQ®) ...

In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose dependent higher rate of VTE ...